Assetmark, Inc Argenx Se Transaction History

Assetmark, Inc

$34.9 Billion
Q3 2024

A detailed history of Assetmark, Inc transactions in Argenx Se stock. As of the latest transaction made, Assetmark, Inc holds 7,769 shares of ARGX stock, worth $4.88 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

7,769

Previous 7,171 8.34%

Holding current value

$4.88 Million

Previous $3.08 Million 36.65%

% of portfolio

0.01%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	BUY	$434.22 - $551.9 $259,663 - $330,036	598 Added 8.34%	7,769 $4.21 Million
Q2 2024 Aug 13, 2024	BUY	$356.01 - $451.55 $275,551 - $349,499	774 Added 12.1%	7,171 $3.08 Million
Q1 2024 May 06, 2024	BUY	$356.95 - $413.29 $270,925 - $313,687	759 Added 13.46%	6,397 $2.52 Million
Q4 2023 Feb 09, 2024	BUY	$338.91 - $506.01 $431,432 - $644,150	1,273 Added 29.16%	5,638 $2.14 Million
Q3 2023 Oct 27, 2023	BUY	$369.35 - $548.43 $237,492 - $352,640	643 Added 17.28%	4,365 $2.15 Million
Q2 2023 Aug 11, 2023	BUY	$360.14 - $422.58 $156,660 - $183,822	435 Added 13.23%	3,722 $1.45 Million
Q1 2023 May 05, 2023	BUY	$334.23 - $403.65 $67,180 - $81,133	201 Added 6.51%	3,287 $1.22 Million
Q4 2022 Feb 10, 2023	BUY	$342.17 - $402.31 $181,007 - $212,821	529 Added 20.69%	3,086 $1.17 Million
Q3 2022 Nov 01, 2022	BUY	$343.2 - $395.75 $158,901 - $183,232	463 Added 22.11%	2,557 $903,000
Q2 2022 Aug 03, 2022	BUY	$269.58 - $378.88 $162,556 - $228,464	603 Added 40.44%	2,094 $793,000
Q1 2022 May 13, 2022	BUY	$254.45 - $351.06 $226,460 - $312,443	890 Added 148.09%	1,491 $470,000
Q4 2021 Feb 14, 2022	BUY	$272.01 - $353.03 $145,797 - $189,224	536 Added 824.62%	601 $210,000
Q3 2021 Nov 12, 2021	BUY	$295.0 - $350.58 $19,175 - $22,787	65 New	65 $20,000

Others Institutions Holding ARGX

# of Institutions

400

Shares Held

30.9M

Call Options Held

376K

Put Options Held

489K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.

Account